We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00483223
Recruitment Status : Completed
First Posted : June 6, 2007
Results First Posted : June 1, 2017
Last Update Posted : August 25, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:

The purpose of this research study is to :

  • Determine how effective cisplatin or carboplatin is in slowing the time it takes for ER negative (estrogen-receptor-negative), PR negative (progesterone receptor-negative), HER2 negative (human epidermal growth factor receptor 2) breast cancer to progress. Cisplatin and carboplatin are anti-cancer chemotherapy drugs that stop cancer cells from growing abnormally and is used to treat other cancers.
  • Evaluate a new biomarker to help determine which breast cancers are most likely to respond to cisplatin chemotherapy

The hypothesis is that Triple Negative metastatic breast cancer may be particularly sensitive to platinum, and that a subgroup of those patients may have a marker in their tumors that predicts response.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Cisplatin Drug: carboplatin Phase 2

Detailed Description:

This study is a Phase 2 study designed to evaluate cisplatin/carboplatin as first or second line therapy in metastatic triple negative (ER negative, PR negative, Her2 Negative) breast cancer and to evaluate the expression of p63/p73 as a biomarker to predict response.

  • Participants will be given a cisplatin or carboplatin infusion intravenously on the first day of each treatment cycle. Each treatment cycle will last 3 weeks. Treating physician will select agent up to 41 patients in each cohort. Final primary endpoint analysis will use combined cis/carbo results.
  • During all treatment cycles participants will have a physical exam (including weight and vital signs) and they will be asked general questions about their health and any medications they may be taking, as well as specific questions about any side effects they may be experiencing while receiving study treatment.
  • During every treatment cycle participants will have standard blood tests to check blood counts, liver and kidney function, and a blood marker for you particular type of cancer.
  • CT scans will be taken of the participants tumor every 2 to 3 cycles to assess the response of the tumor to cisplatin.
  • Participants will be in this study for as long as they tolerate the study treatment and their disease does not get any worse.
  • Participants will be required to have a sample of their original tumor sent to Massachusetts General Hospital for correlative studies, or a sample from a metastatic diagnostic biopsy.
  • Patients with accessible tumor will be asked to provide an optional metastatic tumor biopsy for correlative studies.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Study Start Date : June 2007
Primary Completion Date : June 2014
Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Single Arm
Cisplatin or carboplatin (1 arm, 2 cohorts)
Drug: Cisplatin
Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
Other Name: Platinol
Drug: carboplatin
Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
Other Name: Paraplatin

Outcome Measures

Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: 3 years ]

    Objective response rate (ORR) (complete response [CR]+ partial response [PR]) by RECIST (Response Evaluation Criteria In Solid Tumors).

    Complete Response (CR): Disappearance of all target lesions

    Partial Response (PR): At least a 30% decrease in the sum of the LD (longest diameter) of target lesions, taking as reference the baseline sum LD

    Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started

    Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions

  2. Response Rate Categorized by p63/p73 Ratio [ Time Frame: 3 years ]
    Response rate categorized by pre-specified ΔNp63/TAp73 expression ratio cutoff in the primary tumors from this patient cohort as a bio-marker to predict response to cisplatin or carboplatin. Response is defined as partial or completed response as determined by RECIST. Expression ratio was measured using quantitative RT-PCR (Reverse transcription polymerase chain reaction).

Secondary Outcome Measures :
  1. Objective Response Rate Categorized by Subgroup [ Time Frame: 3 years ]
    The number of participants achieving an objective response (as determined by RECIST) categorized by treatment cohort and whether the treatment was first or second line treatment. First line treatment means that the drug used was the first drug used for the treatment of the primary cancer. Second line treatment means that a first line treatment failed to produce the desired response, so a new drug was used for treatment.

  2. Progression Free Survival and Overall Survival [ Time Frame: 5 years ]
    Median progression free survival and overall survival (progression determined using RECIST) during a median follow-up time of 50 months.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed invasive breast cancer with stage IV disease, according to AJCC 6th edition (American Joint Committee on Cancer), either biopsy proven or with unequivocal evidence of metastatic disease by physical examination or radiological study
  • All tumors must be ER-, PGR- and HER2-negative
  • 18 years of age or older
  • Paraffin tissue block is required from the primary tumor tissue or from diagnostic metastatic biopsy at time of relapse
  • Measurable disease by RECIST
  • Performance status of 0,1 or 2 by ECOG criteria (Eastern Cooperative Oncology Group)
  • Life expectancy greater than 12 weeks
  • Normal organ and bone marrow function documented within 14 days prior to enrollment as defined by the protocol

Exclusion Criteria:

  • More than 1 prior chemotherapy for the treatment of recurrent or metastatic breast cancer
  • Prior treatment with cisplatin, carboplatin, or other platinum chemotherapy agents
  • Active brain metastases or unevaluated neurological symptoms suggestive of brain metastases
  • Intercurrent illness or other major medical condition or comorbid condition that might affect study participation
  • Significant history of uncontrolled cardiac disease such as uncontrolled hypertension, unstable angina, recent myocardial infarction, uncontrolled congestive heart failure, cardiomyopathy either symptomatic or asymptomatic but with decreased ejection fraction <45%
  • Renal dysfunction for which cisplatin dose would either require dose modification or would be considered unsafe
  • Pregnant or nursing women
  • History or other malignancy that was not treated with curative intent
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483223

United States, Alabama
University of Alabama-Birmingham
Birmingham, Alabama, United States
United States, California
San Francisco, California, United States
United States, District of Columbia
Georgetown - Lombardi Cancer Center
Washington, D.C., District of Columbia, United States
United States, Maryland
Johns Hopkins University Medical Center
Baltimore, Maryland, United States
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
North Shore Medical Center
Peabody, Massachusetts, United States, 01960
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States
Sponsors and Collaborators
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
North Shore Medical Center
Principal Investigator: Steven Isakoff, MD, PhD Massachusetts General Hospital
More Information

Responsible Party: Steven Isakoff, MD, PhD, Attending Physician, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00483223     History of Changes
Other Study ID Numbers: 06-412
TBCRC009 ( Other Identifier: Translational Breast Cancer Research Consortium )
First Posted: June 6, 2007    Key Record Dates
Results First Posted: June 1, 2017
Last Update Posted: August 25, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Steven Isakoff, MD, PhD, Massachusetts General Hospital:
ER negative
PgR negative
HER2 negative

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents